Abstract. The purpose of the present study was to identify gene polymorphisms for the reliable assessment of genetic factors for obesity. The study population comprised 3906 unrelated Japanese individuals (2286 men, 1620 women), including 1196 subjects (677 men, 519 women) with obesity (body mass index of ≥25 kg/m 2 ) and 2710 controls (1609 men, 1101 women). The genotypes for 147 polymorphisms of 124 candidate genes were determined with a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology. Multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of smoking revealed that the -30G→A polymorphism of GCK, the -240A→T polymorphism of ACE, and the -482C→T polymorphism of APOC3 were significantly (P<0.01) associated with the prevalence of obesity, and the -1989T→G polymorphism of ESR1 was almost significantly associated. A stepwise forward selection procedure demonstrated that ACE, GCK, and ESR1 genotypes significantly (P<0.01) and independently affected the prevalence of obesity. Combined genotype analysis for these three polymorphisms yielded a lowest odds ratio of 0.45 for the combined genotypes of AT or TT for ACE, GG for GCK, and GG for ESR1 in comparison with the combined genotypes of AA for ACE, GG for GCK, and TT or TG for ESR1. Genotypes for ACE, GCK, and ESR1 may prove reliable for the assessment of genetic factors for obesity. Determination of the combined genotypes for these genes may contribute to the personalized prevention of this condition.
Introduction
The prevalence of obesity, a multifactorial disease caused by an interaction of genetic factors with lifestyle and environmental factors (1) , is rapidly increasing worldwide. A sedentary lifestyle, high-fat and high-energy diet, and genetic predisposition to obesity all contribute to the epidemic. Although genetic linkage analyses (2) (3) (4) (5) and candidate gene approaches (6-9) have implicated several loci and candidate genes in predisposition to obesity, the genes that contribute to genetic susceptibility to this condition remain to be identified definitively. In addition, given the ethnic differences in lifestyle and environmental factors as well as in genetic background, it is important to examine gene polymorphisms related to obesity in each ethnic group.
We have now performed a large-scale association study for 147 candidate gene polymorphisms and obesity in 3906 Japanese individuals. The purpose of the present study was to identify gene polymorphisms for the reliable assessment of the genetic factors for obesity, and thereby to contribute to the personalized prevention of this condition.
Materials and methods
Study population. The study population comprised 3906 unrelated Japanese individuals (2286 men, 1620 women) who either visited outpatient clinics at or were admitted to one of the five participating hospitals (Gifu Prefectural Gifu Hospital, Gifu Prefectural Tajimi Hospital, Gifu Prefectural Gero Hotspring Hospital, Hirosaki University Hospital, and Reimeikyo Rehabilitation Hospital) between October 2002 and March 2005. Obesity was defined as a body mass index (BMI) of ≥25 kg/m 2 on the basis of the BMI criteria for Japanese and Asian populations (10) . A total of 1196 individuals (677 men, 519 women) among the study population were thus classified as obese. The controls comprised a total of 2710 individuals (1609 men, 1101 women) who visited the outpatient clinics of the participating hospitals for an annual health checkup and who had a BMI of <25 kg/m 2 . The study protocol complied with the Declaration of Helsinki and was approved by the Committees on the Ethics of Human Research of Mie University School of Medicine, Hirosaki University School of Medicine, Gifu International Institute of Biotechnology, and the participating hospitals, and written informed consent was obtained from each participant.
Selection of polymorphisms.
With the use of public databases, we selected 124 candidate genes that have been characterized and suggested to be associated with obesity on the basis of a comprehensive overview of: lipid and adipose tissue metabolism, insulin and glucose metabolism, other metabolic factors as well as the regulation of blood pressure and endocrine function, vascular biology, monocyte-macrophage biology, lymphocyte and leukocyte biology, coagulation and fibrinolysis systems and platelet function. We further selected 147 polymorphisms of these genes, most of which are located in the promoter region, exons, or splice donor or acceptor sites of introns and might therefore be expected to result in changes in the function or expression of the encoded protein (Supplementary Table I) .
Genotyping of polymorphisms.
Venous blood (7 ml) was collected in tubes containing 50 mmol/l EDTA (disodium salt), and genomic DNA was isolated with a kit (Genomix; Talent, Trieste, Italy). Genotypes of the 147 polymorphisms were determined (G&G Science, Fukushima, Japan) by a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology (Luminex, Austin, TX). Primers, probes, and other conditions for genotyping are shown in Supplementary Table II . Detailed genotyping methodology was described previously (11) .
Statistical analysis. Clinical data were compared between the subjects with obesity and the controls by the unpaired Student's t-test. Qualitative data were compared by the Chi-square test. Table I . Characteristics of the 3906 study subjects. - Table III . Multivariable logistic regression analysis of polymorphisms related to obesity. 
OR, odds ratio; CI, confidence interval. Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of smoking. P values of <0.01 are shown in bold.
- Each genotype was assessed according to a dominant or recessive model based on statistical significance, and each combined genotype was compared to that which conferred the highest genetic risk for obesity. We also performed a stepwise forward selection procedure to examine the effects of genotypes as well as of other covariates on obesity. The levels for inclusion in and exclusion from the model were 0.25 and 0.1, respectively. Given the multiple comparisons of genotypes with obesity, we adopted a level of P<0.01 for statistical significance of association. For other clinical background data, a P value of <0.05 was considered statistically significant. Statistical significance was examined by two-sided tests, and statistical analyses were performed with JMP version 5.1 software (SAS Institute, Cary, NC).
Results
The characteristics of the 3906 study subjects are shown in Table I . Subjects with obesity were younger and exhibited a higher prevalence of hypertension, hypercholesterolemia, and diabetes mellitus compared with the controls. Systolic and diastolic blood pressure, the serum concentrations of total cholesterol and triglycerides, the fasting plasma concentration of glucose, and the serum level of glycosylated hemoglobin were higher, and the serum concentration of high density lipoprotein-cholesterol was lower, in the subjects with obesity than in the controls. Comparison of genotype distributions with the Chi-square test revealed that nine polymorphisms were related (P<0.05) to the prevalence of obesity (Table II) . These polymorphisms were further analyzed for their possible association with obesity. Multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of smoking revealed that the -30G→A polymorphism of the glucokinase gene (GCK, dominant model), the -240A→T polymorphism of the Table IV . Genotype distribution of polymorphisms related to obesity. Table V . Effects of genotypes and other characteristics on obesity as determined by a stepwise forward selection procedure (P<0.05). 
angiotensin-converting enzyme gene (ACE, dominant and additive 1 models), and the -482C→T polymorphism of the apolipoprotein C-III gene (APOC3, dominant and additive 1 models) were significantly (P<0.01) associated with the prevalence of obesity (Table III) . In addition, the -1989T→G polymorphism of the estrogen receptor · gene (ESR1, recessive model) was almost significantly associated with obesity. The -482T allele of APOC3 represented a risk factor for obesity, whereas the -30A allele of GCK, the -240T allele of ACE, and the -1989G allele of ESR1 were protective against this condition. The genotype distributions of the nine identified polymorphisms were in Hardy-Weinberg equilibrium in both the controls and the subjects with obesity (Table IV) . We next performed a stepwise forward selection procedure to examine the effects of genotypes for these polymorphisms, age, sex, and smoking status on obesity (Table V) . Age, ACE genotype (dominant model), GCK genotype (dominant model), and ERS1 genotype (recessive model), in descending order of statistical significance (P<0.01), each independently affected the prevalence of obesity.
Finally, we calculated the odds ratio, 95% confidence interval, and P value for combined genotypes in assessment of the genetic risk for obesity. Combined genotype analysis of three polymorphisms (-240A→T in ACE, -30G→A in GCK, and -1989T→G in ESR1) revealed that a lowest odds ratio of 0.45 was obtained for the combined genotype of AT or TT for ACE, GG for GCK, and GG for ESR1 in comparison with the combined genotype of AA for ACE, GG for GCK, and TT or TG for ESR1 (Table VI) .
Discussion
We have examined the relations of 147 polymorphisms in 124 candidate genes to obesity. Our large-scale association study with 3906 subjects revealed that the -240A→T polymorphism of ACE, the -30G→A polymorphism of GCK, and the -1989T→G polymorphism of ESR1 were significantly associated with the prevalence of obesity in a Japanese population. Combined genotype analysis of these three polymorphisms yielded a lowest odds ratio of 0.45 for the predisposition to obesity.
The renin-angiotensin system of adipose tissue plays an important role in adipocyte growth and differentiation through the action of angiotensin II (12, 13) . In addition, epidemiologic studies have demonstrated associations between the plasma concentration of angiotensinogen (14, 15) , plasma renin activity (16), or plasma ACE activity (17) with BMI. In adult white men, homozygosity for the D allele of an insertion/deletion (I/D) polymorphism in intron 16 of ACE was associated with a greater prevalence of age-related abdominal adiposity and with a greater tendency to become overweight during 20 years of follow-up, consistent with a role for the local renin-angiotensin system in adipose tissue metabolism and, more generally, with a genetic influence on the control of fat deposition (18) . The I/D polymorphism of ACE was also associated with obesity and abdominal fat deposition in subjects with coronary heart disease; subjects with this condition and the D allele showed a higher prevalence of obesity and abdominal fat deposition as well as higher values for weight and waist circumference (19) . A haplotype in the promoter region of ACE was transmitted preferentially from parents to offspring who became obese among black populations in both the United States and Nigeria, suggesting that ACE polymorphisms may influence the development of weight gain (20) . We have now shown that the -240A→T polymorphism of ACE was significantly associated with the prevalence of obesity, while the T allele protected against this condition. Our results are thus consistent with the previous observations that ACE polymorphisms are related to obesity.
Glucokinase is expressed in pancreatic ß cells and hepatocytes, its expression being controlled by two tissue-specific promoters (21) . Pancreatic glucokinase serves as the sensor for glucose in the regulation of insulin secretion (22) . Mutations of GCK account for 10-50% of cases of maturityonset diabetes of the young (22) . A-30G→A polymorphism located in the ß cell-specific promoter of GCK was shown to be associated with reduced ß cell function and impaired glucose tolerance in Japanese (23,24). We have now shown that this polymorphism is associated with obesity, with the A allele being protective against this condition. The mechanisms responsible for the association of the A variant with reduced -
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OR, odds ratio; CI, confidence interval. Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of smoking.
-
ß cell function and impaired glucose tolerance (23,24) as well as with a reduced risk of obesity (our study) remain to be determined. It is possible that the -30G→A polymorphism of GCK is in linkage disequilibrium with other polymorphisms of nearby genes which are actually responsible for obesity. A lack of ESR1 resulted in white adipocyte hyperplasia and hypertrophy, insulin resistance, and glucose intolerance in both sexes of mice (25). Estrogen-ESR1 signaling thus plays an important role in white adipose tissue of males and females; obesity in ESR1-deficient male mice resulted from reduced energy expenditure rather than increased energy intake. Two single nucleotide polymorphisms have been identified in the first intron of ESR1: a T→C polymorphism that is recognized by the restriction endonuclease Pvu II and an A→G polymorphism that is recognized by Xba I [A and G alleles correspond to the presence (x allele) and absence (X allele) of the restriction site, respectively]. The GG (XX) genotype was found to be significantly more frequent among subjects with type 2 diabetes mellitus and android-type obesity than in healthy individuals (26). The GG (XX) genotype of the Xba I polymorphism was also shown to contribute to the development of android-type fat distribution in middle-aged and premenopausal Japanese women (27). We have now shown that the -1989T→G polymorphism of ESR1 was significantly associated with the prevalence of obesity, with the G allele protecting against this condition. The -1989T→G polymorphism is in linkage disequilibrium with the Xba I polymorphism in Japanese individuals, with the G allele of the former polymorphism being associated with the A (x) allele of the latter (28). The previous observations that the GG (XX) genotype is related to android-type obesity are thus consistent with our present results.
Given the multiple comparisons of genotypes with obesity in the present study, we adopted a strict criterion (P<0.01) for the statistical significance of association. It is not possible, however, to completely exclude potential statistical errors such as false positives. It is also possible that one or more of the polymorphisms associated with obesity in our study are in linkage disequilibrium with polymorphisms of other nearby genes that are actually responsible for the development of this condition. Furthermore, the relevance of the identified polymorphisms to gene transcription or to protein structure or function was not determined in the present study. Despite these limitations, our present results suggest that ACE, GCK, and ESR1 are susceptibility loci for obesity in the Japanese population. Determination of combined genotypes for these polymorphisms may prove informative for assessment of the genetic factors for obesity and may contribute to the personalized prevention of this condition. Table I . The 147 polymorphisms examined in the present study.
Proprotein convertase, subtilisin/kexin-type, 9 PCSK9 23968A→G (Glu670Gly) rs505151 1p22-p21
Coagulation factor III F3 -603A→G rs1361600 1p22.1
Glutamate-cysteine ligase, modifier subunit
Tumor necrosis factor ligand superfamily, member 4 TNFSF4 A→G rs3850641 1q31-q32
Interleukin 10
Insulin receptor substrate 1 IRS1 3931G→A (Gly972Arg) rs1801278 2q37. 3 Calpain 10 CAPN10 4852G→A rs3792267 3pter-p21
Chemokine, CX3C motif, receptor 1 CX3CR1 926C→T (Thr280Met) rs3732378 3p25
Peroxisome proliferator-activated receptor-Á PPARG -681C→G rs10865710 3p25
Peroxisome proliferator-activated receptor-Á PPARG 34C→G (Pro12Ala) rs1801282 3p22
Transforming growth factor-ß receptor, type II TGFBR2
Chemokine, CC motif, receptor 2 CCR2 190G→A (Val64Ile)  rs1799864  3p21 Chemokine, CC motif, receptor 5
Adipocyte, C1Q, and collagen domain containing ACDC -11377C→G rs266729 3q28
Adaptor-related protein complex 2, MU-1 subunit AP2M1 62G→T rs1501299 4p15.1
Peroxisome proliferator-activated receptor-Á, coactivator 1 PPARGC1
Microsomal triglyceride transfer protein, 88-kD
Fibrinogen, B ß polypeptide FGB 8059G→A (Arg448Lys) rs4220 4q28-q31
Fatty acid-binding protein 2 FABP2 2445G→A (Ala54Thr) rs1799883 4q31
Uncoupling protein 1 UCP1 -112A→C rs10011540 4q31. 22 Endothelin receptor, type A EDNRA -231A→G rs1801708 5q12
Phosphodiesterase 4D, cAMP-specific PDE4D TAAA→-(3'-UTR) rs3839219 5q13
Thrombospondin IV THBS4 1186G→C (Ala387Pro) rs1866389 5q13
Phosphatidylinositol 3-kinase, regulatory, 1
Supplementary Table I. Continued.
Tumor necrosis factor TNF -863C→A rs1800630 6p21. 3 Tumor necrosis factor TNF -850C→T rs1799724 6p21. 3 Tumor necrosis factor TNF -238G→A rs361525 6p21. 3 Advanced glycosylation end product-specific receptor AGER 268G→A (Gly82Ser) rs2070600 6p21.2-p21. -
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a In the event that rs numbers in dbSNP were not detected, NCBI GenBank accession numbers are shown in parentheses.
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